Abstract: Retinitis pigmentosa (RP) is the most common hereditary retinal disease. There are many reports on the treatment of RP, including the drugs, laser, surgical, gene and cell therapy. The effectiveness of previous treatments is ambiguous. The emerging gene therapy and cell therapy for RP have shown safety and worth further investigations and randomized clinical trials. In addition, there are some problems in the treatment of RP combined with cataract and other ocular complications. This guideline summarizes treatments of RP and its complications, refers to the latest literatures, and extensively solicits opinions from experts for the reference of ophthalmologists. (Ophthalmol CHN, 2021, 30: 249-258)

Key words:  retinitis pigmentosa/treatment, evidence guideline